Loading
Aortic Disease and Treatment Approaches / Cardiac Valve Diseases and Treatments · Journal article
Mini-invasive Surgery · July 1, 2026
A consensus or society position rather than new primary data.
This is a narrative review identifying three key areas of clinical uncertainty in contemporary TAVR practice: long-term durability and lifetime management, leaflet-modification techniques for complex redo procedures, and the role of cerebral embolic protection. The source synthesizes evidence from randomized trials and guidelines but does not present new empirical results, instead highlighting gaps in knowledge and prompting further investigation.
Journal article. Patients with severe aortic stenosis across risk strata, including intermediate- and low-risk populations and select patients with bicuspic anatomy; increasingly younger patients undergoing TAVR..
Contemporary randomized trials have demonstrated comparable or superior early outcomes of TAVR to surgical aortic valve replacement (SAVR) 2025 European Society of Cardiology recommendations unify the age threshold for TAVR to ≥70 years in appropriately selected patients Long-term valve durability beyond the first decade remains insufficiently defined
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that while TAVR has expanded to lower-risk and younger populations, several critical questions remain: long-term durability data are incomplete, optimal strategies for valve-in-valve procedures are evolving, and the clinical benefit of cerebral embolic protection remains unproven. This review highlights areas requiring further research and structured follow-up protocols before definitive recommendations can be made.
A narrative review synthesizing current evidence and identifying unresolved questions in TAVR practice across three clinical domains, without presenting new primary data or trial results.
Quoted from the source exactly as published.
Clinicians should recognize that while TAVR has expanded to lower-risk and younger populations, several critical questions remain: long-term durability data are incomplete, optimal strategies for valve-in-valve procedures are evolving, and the clinical benefit of cerebral embolic protection remains unproven. This review highlights areas requiring further research and structured follow-up protocols before definitive recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Transcatheter aortic valve replacement (TAVR) has rapidly evolved from a therapy reserved for high-risk surgical candidates to a preferred treatment option across a broad range of patients with severe aortic stenosis. Contemporary randomized trials have demonstrated comparable or superior early outcomes to surgical aortic valve replacement (SAVR), leading to expanded indications in intermediate- and low-risk populations, as well as select patients with bicuspid anatomy. Recent guideline updates, including the 2025 European Society of Cardiology recommendations, unify the age threshold for TAVR to ≥ 70 years in appropriately selected patients and support consideration of early intervention in asymptomatic severe aortic stenosis based on emerging evidence. As younger patients increasingly undergo TAVR, several key uncertainties have become central to clinical decision-making. Long-term valve durability beyond the first decade remains insufficiently defined, emphasizing the need for structured lifetime management strategies that account for anticipated reinterventions, prosthesis-patient mismatch, and coronary access preservation. The rise in valve-in-valve and redo-TAVR procedures introduces complex anatomical challenges, including coronary obstruction and sinus sequestration, which has driven the development of advanced leaflet-modification techniques. In parallel, the role of cerebral embolic protection (CEP) remains uncertain, as randomized trials have demonstrated neutral results, leading to ongoing investigation into which patients may benefit and which technologies may offer meaningful protection. This review synthesizes current evidence and unresolved questions in three domains essential to contemporary TAVR practice: lifetime management, leaflet modification strategies, and CEP.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.